Complete Genomics Lays off 20 Percent of Workforce, Considers 'Strategic Alternatives' | GenomeWeb

Complete Genomics is laying off 20 percent of its workforce in order to reduce its cash burn and has hired a financial advisor to explore strategic alternatives, the company said today.

The layoffs, which will affect about 55 employees in the field service and sequencing factory at its Mountain View, Calif., headquarters and other US locations, will be substantially completed by June 30. The company expects restructuring costs of approximately $1.5 million, mostly in termination benefits, that will be recorded this quarter.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.